A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors

Autor: Lenz, H.-J., Argilés, G., de Jonge, M.J.A., Yaeger, R., Doi, T., El-Khoueiry, A., Eskens, F., Kuboki, Y., Bertulis, J., Nazabadioko, S., Pronk, L., Tabernero, J.

Publikováno v: In ESMO Open November 2024 9(11)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases.

Autor: Deterding R; Section of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Colorado Denver, Denver, CO, USA.; The Children's Hospital Colorado, Aurora, CO, USA.; These two authors contributed equally., Young LR; Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.; These two authors contributed equally., DeBoer EM; Section of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Colorado Denver, Denver, CO, USA.; The Children's Hospital Colorado, Aurora, CO, USA., Warburton D; Children's Hospital Los Angeles, Los Angeles, CA, USA.; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Cunningham S; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK., Schwerk N; Clinic for Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany., Flaherty KR; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA., Brown KK; Department of Medicine, National Jewish Health, Denver, CO, USA., Dumistracel M; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany., Erhardt E; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Bertulis J; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Gahlemann M; Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland., Stowasser S; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Griese M; Hauner Children's Hospital, Ludwig Maximilians University, German Center for Lung Research (DZL), Munich, Germany.

Publikováno v: The European respiratory journal [Eur Respir J] 2023 Feb 02; Vol. 61 (2). Date of Electronic Publication: 2023 Feb 02 (Print Publication: 2023).

Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.

Autor: Lingvay I; Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, UT Southwestern Medical Center , Dallas, TX, USA., Beetz N; Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany., Sennewald R; Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany., Schuler-Metz A; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany., Bertulis J; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany., Loley C; Biostatistics and Data Sciences, Clinical Statistics, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany., Lang B; Biostatistics and Data Sciences, Clinical Statistics, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany., Lippert C; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riß, Germany., Lee J; Clinical Development & Cardiometabolism and Respiratory Medicine, Boehringer Ingelheim International GmbH , Ingelheim, Germany., Manning LS; Clinical Development & Medical Affairs - Cardiometabolism, Boehringer Ingelheim Pharmaceuticals Inc , Ridgefield, CT, USA., Terada D; Clinical Development & Medical Affairs - Cardiometabolism, Boehringer Ingelheim Pharmaceuticals Inc , Ridgefield, CT, USA.

Publikováno v: Postgraduate medicine [Postgrad Med] 2020 May; Vol. 132 (4), pp. 337-345. Date of Electronic Publication: 2020 May 04.

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.

Autor: Rahban, Mahdie¹ mrohban@ut.ac.ir, Joushi, Sara¹, Bashiri, Hamideh², Saso, Luciano³, Sheibani, Vahid¹ vsheibani@kmu.ac.ir, Tasso, Bruno

Publikováno v: Frontiers in Chemistry. 2024, p1-17. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.